UroGen Pharma(URGN) ZACKS·2024-12-02 23:45Core Viewpoint - Urogen Pharma (URGN) shows significant upside potential with a mean price target of 12.70 [1] Price Target Analysis - The average price target consists of seven estimates ranging from 64, with a standard deviation of $15.76, suggesting variability in analyst predictions [2] - The lowest estimate indicates a potential increase of 41.7%, while the highest suggests a 403.9% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [7] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about URGN's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [9] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 11.2%, with four estimates moving higher and no negative revisions [10] - URGN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as they can often mislead investors [5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]